Escolar Documentos
Profissional Documentos
Cultura Documentos
2022;44(S2):S1−S689 S347
quando somadas as duas induç o ~ es. Discussa~ o: O resultado do their reporting is essential for the identification of new cyto-
tratamento da LMA pedia trica melhorou significativamente genetic prognostic risk groups and possible alterations associ-
nas u ltimas de cadas. As taxas de Sobrevida Global (SG) atuais ated with the MDS pathogenesis.The aim of this study was
~ o superiores a 70%, devido a
sa implementaç a ~ o de estrategias describe a yet unreported der(2)t(2;15)(q37;q21) in a de novo p-
como classificaç a ~ o de risco mais precisa, refinamentos nos MDS associated with evolution to AML. Material and meth-
cuidados de suporte e acesso ao transplante. No entanto, em ods: Cytogenetic analysis was performed in Bone Marrow
locais com recursos limitados e países em desenvolvimento, (BM) cells by G-banding. Fluorescence In Situ Hybridization
como o Brasil, a SG varia de 20% a 55%, conforme a regia ~ o do (FISH) was performed to investigate the possible rearrange-
país, e as mortes relacionadas ao tratamento de induç ao sa ~ ~o ment involving chromosomes 2 and 15, using a Whole Chro-
excepcionalmente altas (entre 25%‒30% de o bitos nos pri- mosome Painting (WCP) probe for chromosome 2 and LSI
meiros dois meses de tratamento, contra discrepantes menos PML/RARA for chromosome 15 (PML gene). Results: A 12-year-
de 5% nos países de primeiro mundo). Os regimes com qui- old girl was admitted to the Pediatrics Institute of Federal Uni-
mioterapia de dose padra ~ o esta ~ o associados a complicaç o ~ es versity of Rio de Janeiro in January 2022. Peripheral blood
com risco de vida, devido a profunda mielossupressa ~o e count showed Hemoglobin (Hb) level of 6.5 g/dL, 794.000 plate-
disfunç a~ o orga
^ nica. Ha
atualmente dados suficientes na lit- lets/mm3, and 2.600 white blood cell (WBC)/mm3. The myelo-
eratura, que suportam o risco de utilizar protocolos com gram showed dysplasias and 16% of myeloid blasts being
baixas doses de induç a ~ o na LMA. Como demonstrado pelos classified with MDS-EB-t. The conventional cytogenetic analy-
bons resultados do grupo chine ^s (reproduzidos em outros sis showed the karyotype: 46,XX,add(2)(q37?)[25]. Using
países e contextos, inclusive na America Latina), e possível molecular cytogenetic methods, we characterized the chro-
observar taxas índices de remissa ~ o completa e sobrevida mosomal alteration as an unbalanced translocation involving
similares aos protocolos internacionais que fazem uso de chromosomes 2 and 15. This translocation was observed in
poliquimioterapia em altas doses. Os resultados dos pri- 71.6% (190/265) of the interphase nuclei and metaphases. The
meiros 67 pacientes que receberam o protocolo MAG no final karyotype was: 46,XX,der(2)t(2;15)(q37;q21)[25]. Five
Brasil demonstram isso, com mortalidade inferior a 9% months later, the patient showed in the myelogram 50.7% of
durante os dois primeiros meses de tratamento, sem pre- blast cells compatible with AML. The patient was indicated
juízo na induç a ~o da remissa ~ o. Conclusa ~ o: Houve reduç a ~o for allogeneic Hematopoietic Stem Cell Transplantation
importante da mortalidade induto ria com o protocolo MAG, (HSCT) and initiated chemotherapy. Discussion: In p-MDS,
com taxas índices de remissa ~o completa similares aos proto- chromosomal translocations as sole chromosomal abnormal-
colos internacionais estandardizados. Os resultados deste ity are rare and their real prognostic impact is unknown. The
estudo contribuem para a adesa ~o a proposta do novo proto- patients with this type of cytogenetic alteration are classified
colo da Sociedade Brasileira de Oncologia Pedia trica as intermediate-risk group according to the IPSS-R. Our report
(SOBOPE) para LMA pedia trica, aprovado em maio de 2022 describes the clinical outcome in a novo p-MDS showing a der
(CAAE 51679421.6.1001.0098) e ja em aplicaç a ~ o em 45 (2)t(2;15)(q37;q21). A broad scientific review showed that the
~ es brasileiras.
instituiç o der(2)t(2;15)(q37;q21) was not yet reported in p-MDS. It is
interesting to note that this chromosomal translocation was
https://doi.org/10.1016/j.htct.2022.09.585 associated with a poor clinical outcome, with progression
from MDS to AML. The cytogenetic and clinical features were
important tools for the indication to allogeneic HSCT. Conclu-
NOVEL CHROMOSOMAL ALTERATION DER(2)T sion: This study and literature review highlight the impor-
(2;15)(Q37;Q21) IN A PEDIATRIC PATIENT tance of cytogenetics and clinical follow-up of de novo p-MDS
WITH MYELODYSPLASTIC SYNDROME: patients for the identification for HSCT. This is the first study
MOLECULAR CYTOGENETIC STUDIES that describe the der(2)t(2;15)(q37;q21) in a p-MDS associated
VL Lovatel a, EF Rodrigues a, L Otero a, BF Silva a, with AML evolution.
APS Bueno b, EC Sobral b, TS Fernandez a
https://doi.org/10.1016/j.htct.2022.09.586
a
Cytogenetic Laboratory, Instituto Nacional do
Ca^ ncer (INCA), Rio de Janeiro, RJ, Brazil
b
Faculdade de Medicina, Pediatria e Puericultura e
DIABETES INSIPIDUS COMO APRESENTAÇ AO
Instituto Martaga ~ o Gesteira (IPPMG), Universidade
INICIAL DE HISTIOCITOSE DE CELULAS DE
Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, LANGERHANS (HCL) − RELATO DE CASO
Brazil
LN Cruz a, CE Avila a, DT Vianna a, APS Bueno a,
Objective: Pediatric Myelodysplastic Syndrome (p-MDS) com- MGP Land a, TA Bonilha a, DB Aranha a,
prises a heterogeneous group of clonal hematopoietic stem M Agostini b, MAR Souza a, RSP Silva a
cell diseases with an increased risk of evolution to Acute Mye- a
Instituto de Puericultura e Pediatria Martaga ~o
loid Leukemia (AML). Cytogenetic is one of the most impor-
Gesteira, Universidade Federal do Rio de Janeiro
tant prognostic factors for MDS and it is present into score
(IPPMG/UFRJ), Rio de Janeiro, RJ, Brasil
prognostic systems as the Revised International Prognostic b
Faculdade de Odontologia, Universidade Federal
Scoring System (IPSS-R). Chromosomal translocations are
do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brasil
rare cytogenetic abnormalities in de novo MDS. Therefore,
S348 hematol transfus cell ther. 2022;44(S2):S1−S689